Malaria immunoepidemiology in low transmission: Correlation of infecting genotype and immune response to domains of Plasmodium falciparum merozoite surface protein 3

Infection and Immunity

Volumn 79, Issue 5, 2011, Pages 2070-2078

  Jordan, Stephen J ^a,b   Oliveira, Ana L ^a   Hernandez, Jean N ^c   Oster, Robert A ^d   Chattopadhyay, Debasish ^a   Branch, OraLee H ^e   Rayner, Julian C ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSIDAD NACIONAL DE LA AMAZONÍA PERUANA   (Peru)

^d University of Alabama at Birmingham   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M ANTIBODY; PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 3 ANTIBODY; PROTOZOAL VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CIRCULAR DICHROISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; IMMUNE RESPONSE; MALARIA; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMANS; MALARIA, FALCIPARUM; PERU; PROTOZOAN PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79955617234     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01332-10     Document Type: Article

References (39)

1. Branch, O., et al. 2005. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malar. J. 4:27.
2. Burgess, B. R., P. Schuck, and D. N. Garboczi. 2005. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J. Biol. Chem. 280:37236-37245.
3. Coppel, R. L. 2009. Vaccinating with the genome: a Sisyphean task? Trends Parasitol. 25:205-212.
4. Demanga, C. G., et al. 2010. Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans. Infect. Immun. 78:486-494.
5. Druilhe, P., et al. 2005. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2:e344.
6. Escalante, A. A., A. A. Lal, and F. J. Ayala. 1998. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 149:189-202.
7. Greenwood, B., and G. Targett. 2009. Do we still need a malaria vaccine? Parasite Immunol. 31:582-586.
8. Hisaeda, H., et al. 2002. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J. Infect. Dis. 185:657-664.
9. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
10. Holder, A. A. 2009. Malaria vaccines: where next? PLoS Pathog. 5:e1000638.
11. Huber, W., et al. 1997. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol. Biochem. Parasitol. 87:231-234.
12. Jordan, S. J., O. H. Branch, J. C. Castro, R. A. Oster, and J. C. Rayner. 2009. Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment. Am. J. Trop. Med. Hyg. 80:479-486.
13. Lusingu, J. P., et al. 2009. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar. J. 8:163.
14. Mamillapalli, A., et al. 2007. Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates. Malar. J. 6:95.
15. McColl, D. J., and R. F. Anders. 1997. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface pro-tein-3 (MSP-3). Mol. Biochem. Parasitol. 90:21-31.
16. McColl, D. J., et al. 1994. Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 68:53-67.
17. Nebie, I., et al. 2009. Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunol. 31:474-480.
18. Ochola, L. I., et al. 2010. Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol. Biol. Evol. 27:2344-2351.
19. Oeuvray, C., et al. 1994. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem. Inst. Oswaldo Cruz 89(Suppl. 2):77-80.
20. Oeuvray, C., et al. 2000. Cytophilic immunoglobulin responses to Plasmo-dium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect. Immun. 68:2617-2620.
21. Ogutu, B. R., et al. 2009. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4:e4708.
22. Osier, F. H., et al. 2007. Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. Parasite Immunol. 29:387-394.
23. Osier, F. H., et al. 2010. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect. Immun. 78:4625-4633.
24. Polley, S. D., et al. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23:718-728.
25. Polley, S. D., et al. 2007. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J. Infect. Dis. 195:279-287.
26. Roussilhon, C., et al. 2007. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 4:e320.
27. Sagara, I., et al. 2009. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27:3090-3098.
28. Saul, A. 2007. Malaria vaccines based on the Plasmodium falciparum mero-zoite surface protein 3-should we avoid amino acid sequence polymorphisms or embrace them? J. Infect. Dis. 195:171-173.
29. Singh, S., et al. 2004. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J. Infect. Dis. 190:1010-1018.
30. Singh, S., et al. 2009. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS One 4:e5410.
31. Sirima, S. B., et al. 2007. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 25:2723-2732.
32. Sirima, S. B., et al. 2009. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One 4:e7549.
33. Stanisic, D. I., et al. 2009. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect. Immun. 77:1165-1174.
34. Sutton, P. L., E. H. Clark, C. Silva, and O. H. Branch. 2010. The Plasmo-dium falciparum merozoite surface protein-1 19 KD antibody response in the Peruvian Amazon predominantly targets the non-allele specific, shared sites of this antigen. Malar. J. 9:3.
35. Sutton, P. L., V. Neyra, J. N. Hernandez, and O. H. Branch. 2009. Plasmodium falciparum and Plasmodium vivax infections in the Peruvian Amazon: propagation of complex, multiple allele-type infections without super-infection. Am. J. Trop. Med. Hyg. 81:950-960.
36. Takala, S. L., and C. V. Plowe. 2009. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming "vaccine resistant malaria." Parasite Immunol. 31:560-573.
37. Taylor, R. R., S. J. Allen, B. M. Greenwood, and E. M. Riley. 1998. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am. J. Trop. Med. Hyg. 58:406-413.
38. Tetteh, K. K., et al. 2009. Prospective identification of malaria parasite genes under balancing selection. PLoS One 4:e5568.
39. Trucco, C., et al. 2001. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol. Biochem. Parasitol. 112:91-101.